Reflector

What to make of the simmering public and political angst

With a new Commission looming, here’s who’s vying for the top spot in shaping EU strategy, including key questions in pharma.

European industry fights over every inch on comparative drug pricing initiative.

Europe slow to action on emerging technologies, but the complex issues clouding EHRs and gene editing, for example, offer pause.

Despite a “temporary fix” at the ready, pharma supply repercussions loom if exit deal isn’t reached this month.

“You wanna play rough? Just try it!” was the gist of the New-Year message from the European pharma industry to the healthcare authorities circling around drug firms preparing for pricing discussions. Reflector reports.

Pair of EU meetings, while well-meant, offered little action and beg the question-what’s the true merit in working together?

The European Union is moving ahead, in its own slightly crabwise fashion, with its attempts to work out what healthcare budgets should be used for. Reflector reports.

The EMA might have expected that the publication of its plan for proactive release of clinical reports would receive a warm welcome. But, Reflector writes, it is far from a roaring success.

An escalating political debate over pharma pricing and reimbursement nears the boiling point.